



PTO/SB/D&A (04-03)


Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Complete if Known	
	Application Number	09/250,056
	Filing Date	February 12, 1999
	First Named Inventor	James D. Marks
	Group Art Unit	1642
	Examiner Name	Larry R. Helms
	Attorney Docket Number	407J-895030US
Date Submitted	December 21, 2004	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
SM	1	5,885,793		Griffiths et al.	03-23-1999	
	2	5,733,782	A	Dorai et al.	03-31-1998	
	3	6,054,312		Larocca et al.	04-25-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
SM	4	WO	94/13804	A	Cambridge Antibody Tech	06-23-1994		
	5	WO	94/26787	A1	The Board of Trustees of the Lealand Stanford Junior University	11-24-1994		
	6	WO	99/10014	A	Selective Genetics, Inc.	03-04-1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
SM	7	ADAMS ET AL. (1998) "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies." <i>Cancer Research</i> 58(3): 485-490.		
	8	ANDERSEN ET AL. (1996) "A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells," <i>Proceedings of the National Academy of Sciences</i> 93(5): 1820-1824.		
	9	CAI ET AL. (1995) "Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: Selection of specific antibodies from single-chain Fv fusion phage libraries." <i>Proceedings of the National Academy of Sciences</i> 92(14): 6537-6541.		
	10	DE KRUIF ET AL. (1995) "Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library." <i>Proceedings of the National Academy of Sciences</i> 92(6): 3938-3942.		
	11	DE KRUIF ET AL. (1995) "Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions." <i>Journal of Molecular Biology</i> 248(1): 97-105.		
Examiner Signature			Date Considered	3/10/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)


## Complete if Known

Application Number	09/250,056
Filing Date	February 12, 1999
First Named Inventor	James D. Marks
Group Art Unit	1642
Examiner Name	Larry R. Helms
Attorney Docket Number	407J-895030US
Date Submitted	December 21, 2004

12	DOUGLAS ET AL. (1996) "Targeted gene delivery by tropism-modified adenoviral vectors." <i>Nature Biotechnology</i> 14:1574-1578.
13	VAN EWIJK ET AL. (1997) "Subtractive isolation of phage-displayed single-chain antibodies to thymic stromal cells by using intact thymic fragments." <i>Proceedings of the National Academy of Sciences</i> 94: 3903-3908.
14	GRIFFITHS ET AL. (1994) "Isolation of high affinity human antibodies directly from large synthetic repertoires." <i>The EMBO Journal</i> 13(14): 3245-3260.
15	HUDZIAK ET AL. (1989) "p185 <sup>HER2</sup> Monoclonal Antibody has Antiproliferative Effects in vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor." <i>Molecular and Cellular Biology</i> 9(3): 1165-1172.
16	KASAHARA ET AL. (1994) "Tissue-Specific Targeting of Retroviral Vectors Through Ligand-Receptors Interactions." <i>Science</i> 266: 1373-1376.
17	LEWIS ET AL. (1993) "Differential responses of human tumor cell lines to anti-p185 <sup>HER2</sup> monoclonal antibodies." <i>Cancer, Immunology, Immunotherapy</i> 37(4): 255-263.
18	MARKS ET AL. (1992) "Molecular Evolution of Proteins on Filamentous Phage." <i>Journal of Biological Chemistry</i> 267(23): 16007-16010.
19	MARKS ET AL. (1993) "Human Antibody Fragments Specific for Human Blood Group Antigens from a Phage Display Library." <i>BioTechnology</i> 11(10): 1145-1149.
20	MICHAEL ET AL. (1994) "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway." <i>Gene Therapy</i> 1(4): 223-232.
21	NISSIM ET AL. (1994) "Antibody fragments from a 'single pot' phage display library as immunochemical reagents." <i>The EMBO Journal</i> 13(3): 692-698.
22	PEREIRA ET AL. (1997) "A model system for detection and isolation of a tumor cell surface antigen using antibody phage display." <i>Journal of Immunological Methods</i> 203(1): 11-24.
23	SHEETS ET AL. (1998) "Efficient construction of a large nonimmune phage antibody library." <i>Proceedings of the National Academy of Sciences</i> 95(11): 6157-6162.
24	SOMIA ET AL. (1995) "Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to <i>in vivo</i> gene delivery." <i>Proceedings of the National Academy of Sciences</i> 92(16): 7570-7574.
25	STANCOVSKI ET AL. (1991) "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth." <i>Proceedings of the National Academy of Sciences</i> 88(19): 8691-8698.
26	STAUSBØL-GRØN ET AL. (1996) "A model phage display subtraction method with potential for analysis of differential gene expression." <i>FEBS Letters</i> 391: 71-75.

Examiner Signature	<i>[Signature]</i>	Date Considered	3/20/06
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	09/250,056
	Filing Date	February 12, 1999
	First Named Inventor	James D. Marks
	Group Art Unit	1642
	Examiner Name	Larry R. Helms
	Attorney Docket Number	407J-895030US
Date Submitted	December 21, 2004	

27	ULLRICH ET AL. (1990) "Signal Transduction by Receptors with Tyrosine Kinase Activity." <i>Cell</i> 61(2): 203-212.	
28	VAUGHAN ET AL. (1996) "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library." <i>Nature Biotechnology</i> 14: 309-314.	
29	WATKINS ET AL. (1997) "The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery." <i>Gene Therapy</i> 4(10): 1004-1012.	
30	WATTERS ET AL. (1997) "An optimized method for cell-based phage display panning." <i>Immunotechnology</i> 3: 21-29.	
31	YARDEN (1990) "Agonistic antibodies stimulate the kinase encoded by the <i>neu</i> protooncogene in living cells but the oncogenic mutant is constitutively active." <i>Proceedings of the National Academy of Sciences</i> 87(7): 2569-2573.	

Examiner Signature		Date Considered	3/20/06
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.